Retatrutide (Triple-G)
Also known as: Reta, Triple Agonist, GGG Agonist
An investigational single-molecule triple receptor agonist producing some of the largest weight-loss results seen to date.
Components
How it's combined
In clinical research, retatrutide (Eli Lilly) activates GLP-1, GIP, and glucagon receptors in one molecule, with Phase 3 data showing roughly 28% average weight loss at higher doses. Once-weekly subcutaneous in trials; FDA approval anticipated around late 2026-2027. Often discussed as a standalone rather than a multi-peptide stack, and sometimes paired with cagrilintide in experimental circles.
Available from vendors
PeptideChat is an independent research resource, not the seller. Links go to third-party vendors; products are sold strictly as research chemicals and are not intended for human consumption.
Independent research resource
Not a seller — PeptideChat doesn't sell or ship products.
Research-use-only framing
Content is educational, not a dosing recommendation.
Vendor links clearly disclosed
Outbound links to third-party vendors are always labeled.